<DOC>
	<DOCNO>NCT01923207</DOCNO>
	<brief_summary>The purpose study assess safety tolerability study drug ( DX-2930 ) administer subcutaneously healthy subject . Subjects randomize receive DX-2930 placebo .</brief_summary>
	<brief_title>A Single Increasing Dose Study Assess Safety Tolerability DX-2930 Healthy Subjects</brief_title>
	<detailed_description>Approximately 32 healthy subject randomize receive DX-2930 placebo .</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<criteria>1 . Male female subject 18 55 year age , inclusive . 2 . Willing able read , understand , sign inform consent form . 3 . Willing able receive subcutaneous injection . 4 . Body mass index ( BMI ) 18 33 kg/m2 weight least 60 kg male least 50 kg female , maximum weight 130 kg subject . 5 . Medically healthy determine investigator via assessment physical examination , medical history , clinical laboratory test , vital sign , electrocardiogram ( ECG ) . 6 . Females childbearing potential must agree abstinent else use two follow medically acceptable form contraception Screening Period 30 day final study visit : condom spermicidal jelly , diaphragm cervical cap spermicidal jelly , intrauterine device ( IUD ) . A female whose male partner vasectomy must agree use one additional form medically acceptable contraception . Female subject must agree practice birth control method 30 day final study visit safety precaution . 7 . Females nonchildbearing potential , define surgically sterile ( status post hysterectomy , bilateral oophorectomy , bilateral tubal ligation ) postmenopausal least 12 month ( confirm screen folliclestimulating hormone ( FSH ) level postmenopausal range ) , require contraception study . 8 . Males female partner childbearing potential must agree use highly effective , medically acceptable form contraception screen period 60 day final study visit . All male subject , include male surgically sterile ( post vasectomy ) , must agree practice birth control method 60 day final study visit safety precaution . 1 . Any active acute chronic illness screening . 2 . Any history exposure biologic within 90 day prior dose . 3 . Receipt investigational ( nonlicensed , nonapproved ) drug device within 60 day prior dose . 4 . Any prior history exposure monoclonal antibody . 5 . Pregnant actively breastfeed . 6 . Any history substance abuse dependence . 7 . Positive urine drug alcohol test screen Day 1 amphetamine , benzodiazepine , barbiturate , cocaine , cotinine ( detection mechanism nicotine ) , marijuana , opiates , phencyclidine ethanol . 8 . Regular use alcohol within six month prior screen visit [ fourteen unit alcohol per week ( 1 Unit = 150 mL wine , 360 mL beer , 45 mL 40 % alcohol ) ] . 9 . Use prescription overthecounter medication within 14 day prior administration study medication , use overthecounter product ( dietary herbal supplement vitamin ) within 14 day prior administration study medication . 10 . Use nicotine nicotinecontaining product within previous three month prior screen . 11 . Subject condition , opinion investigator may compromise safety compliance would preclude subject successful completion study interfere interpretation result . 12 . Abnormal clinical laboratory value and/or study assessment ECG result deem clinically significant investigator . 13 . Donation blood within 60 day precede Study Day 1 . 14 . Serology test positive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>